These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32741735)

  • 1. Clinical outcomes of childhood Langerhans cell histiocytosis in Taiwan: A single-center, 20-year experience.
    Wang DS; Lu MY; Yang YL; Lin DT; Lin KH; Chang HH; Jou ST
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):594-601. PubMed ID: 32741735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of pediatric patients with newly diagnosed rhabdomyosarcoma treated by two consecutive protocols - A single institution report in Taiwan.
    Chou SW; Chang HH; Lu MY; Yang YL; Lin DT; Lin KH; Jou ST
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):332-340. PubMed ID: 29903549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solitary tibial lesion as the initial presentation of Langerhans cell histiocytosis: report of two cases and literature review.
    Lin CY; Lee CC; Wu KW; Yuan CT; Kuo KN; Wang TM
    J Int Med Res; 2021 Jan; 49(1):300060520982826. PubMed ID: 33472472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
    Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
    Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
    [No Abstract]   [Full Text] [Related]  

  • 6. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study.
    Morimoto A; Ikushima S; Kinugawa N; Ishii E; Kohdera U; Sako M; Fujimoto J; Bessho F; Horibe K; Tsunematsu Y; Imashuku S;
    Cancer; 2006 Aug; 107(3):613-9. PubMed ID: 16804933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
    Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China.
    Su M; Gao YJ; Pan C; Chen J; Tang JY
    Pediatr Hematol Oncol; 2018; 35(7-8):385-392. PubMed ID: 30693828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
    Huang JB; Xue HM; Chen YY; Huang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
    Monsereenusorn C; Suwannaying K; Techavichit P; Sathitsamitphong L; Komvilaisak P; Rujkijyanont P; Seksarn P; Charoenkwan P; Pakakasama S
    Int J Hematol; 2022 Apr; 115(4):563-574. PubMed ID: 35099760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric langerhans cell histiocytosis: single center experience over a 17-year period.
    İnce D; Demirağ B; Özek G; Erbay A; Ortaç R; Oymak Y; Kamer S; Yaman Y; Kundak S; Vergin C
    Turk J Pediatr; 2016; 58(4):349-355. PubMed ID: 28276205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and treatment outcome of Langerhans cell histiocytosis: 22 years' experience of 154 patients at a single center.
    Lee JW; Shin HY; Kang HJ; Kim H; Park JD; Park KD; Kim HS; Park SH; Wang KC; Ahn HS
    Pediatr Hematol Oncol; 2014 Apr; 31(3):293-302. PubMed ID: 24397251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Outcome Comparison of Pediatric Langerhans Cell Histiocytosis Treated with Modified DAL-HX83/90 or JLSG-96 Protocol].
    Huang JB; Jiang L; Chen C; Xue HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1190-5. PubMed ID: 27531798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Childhood Langerhans cell histiocytosis increased during El Niño 1997-98: a report from the Taiwan Pediatric Oncology Group.
    Chen RL; Lin KS; Chang WH; Hsieh YL; Chen BW; Jaing TH; Yang CP; Hung IJ; Peng CT; Shu SG; Lu MY; Jou ST; Lin KH; Lin DT; Lin MT; Chen JS; Liu HC; Chen SH; Liang DC; Chiou SS; Chang TT; Sheen JM; Hsiao CC; Cheng SN; Lin JC
    Acta Paediatr Taiwan; 2003; 44(1):14-20. PubMed ID: 12800378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
    Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
    Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia.
    Liang DC; Yang CP; Lin DT; Hung IJ; Lin KH; Chen JS; Hsiao CC; Chang TT; Peng CT; Lin MT; Chang TK; Jaing TH; Liu HC; Wang LY; Yeh TC; Jou ST; Lu MY; Cheng CN; Sheen JM; Chiou SS; Wu KH; Hung GY; Chen RL; Chen SH; Cheng SN; Chang YH; Chen BW; Ho WL; Wang JL; Lin ST; Hsieh YL; Wang SC; Chang HH; Yang YL; Huang FL; Chang CY; Chang WH; Lin KS
    Leukemia; 2010 Feb; 24(2):397-405. PubMed ID: 20016538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
    Morimoto A; Shioda Y; Kudo K; Kanegane H; Imamura T; Koh K; Kosaka Y; Yuza Y; Nakazawa A; Saito AM; Watanabe T; Nakazawa Y
    Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of treatment in childhood Langerhans cell histiocytosis based on inflammatory and malignant symptoms: a pilot study.
    Lin HL; Zheng QQ; Huang RL; Hu R; Liu XD; Wang JY
    Orphanet J Rare Dis; 2024 Apr; 19(1):174. PubMed ID: 38654381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.
    Tazi A; Lorillon G; Haroche J; Neel A; Dominique S; Aouba A; Bouaziz JD; de Margerie-Melon C; Bugnet E; Cottin V; Comont T; Lavigne C; Kahn JE; Donadieu J; Chevret S
    Orphanet J Rare Dis; 2017 May; 12(1):95. PubMed ID: 28532436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.